Insights on Clinical Trials

  1. What Do Cancer Patients Really Want From mHealth Technology? 9/30/2025

    The success of mobile health (mHealth) tools depends on whether patients want to use them. Patient perspectives can guide design to reduce burden, build trust, and make digital tools truly meaningful.

  2. Rethinking Recruitment: Patient-Centric Strategies For The Future Of Clinical Trials 9/30/2025

    For sponsors and CROs, the message is clear: recruitment must be redesigned for accessibility, inclusivity, and patient trust.

  3. Navigating Adverse Immunostimulation: A Practical Guide For Clinical Researchers 9/30/2025

    Explore a systematic approach to evaluate adverse immunostimulation (AIS) in drug development through standardized biomarker sampling and tailored management strategies.

  4. Driving Prostate Cancer Innovation Through Immunotherapy With OS Therapies' Dr. Robert Petit 9/26/2025

    OS Therapies' Dr. Robert Petit discusses the evolving role of immunotherapy in prostate cancer.

  5. Phase I Clinical Trial Designs: Bayesian Logistic Regression Model (BLRM) 9/25/2025

    The Bayesian Logistic Regression Model (BLRM) is redefining Phase I clinical trial design by bringing flexibility, precision, and patient-centered safety into early drug development.

  6. Phase I Clinical Trial Designs: Continuous Reassessment Method (CRM) 9/25/2025

    The benefits are clear: CRM accelerates dose finding, reduces patient exposure to unsafe doses, and improves trial efficiency.

  7. Effect Of Etrasimod On Immune Cell Subsets In Colonic Tissue 9/25/2025

    Etrasimod selectively modulates S1P receptors to reduce inflammation and immune cell trafficking to the gut, showing promise in treating moderate to severe ulcerative colitis.

  8. Phase 1 Clinical Trial Designs Explained: BOIN, CRM, BLRM, And Modern Adaptive Strategies 9/25/2025

    As precision medicine evolves, trial designs must increasingly accommodate personalized therapies, adaptive strategies, and AI-driven modeling.

  9. Conducting Autologous Cell Therapy Research With Zero Sample Loss 9/25/2025

    Autologous cell therapy trials require precision at every stage—and this biomarker-specific solid tumor study exemplified the challenge.

  10. FDA Draft Guidance On Overall Survival in Oncology Trials 9/25/2025

    Historically regarded as the gold standard efficacy endpoint, Overall Survival (OS) in oncology trials is now positioned not only as a measure of therapeutic benefit but also as a critical safety endpoint.